35 results
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Jun 24
Current report (foreign)
4:47pm
. Previously, he was with Pfizer Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer’s La Jolla Laboratories … . Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
manufacturing activity, and lower personnel costs due to fewer research and development headcount compared to prior year.
Administrative expenses … December 31,
(in USD thousands)
Research and development expenses
Administrative expenses
Net impairment losses
Other income
Other (losses)/gains - net
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
.
1.18. “Develop” or “Development” shall mean to conduct any non-clinical or clinical drug research or development activities, whether before or after
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
as of December 31, 2022. The decrease was mainly due to ongoing research and development (R&D) costs associated with the Company’s clinical drug programs … )
Research and development expenses
Administrative expenses
Other income
Other gains - net
Operating loss
Finance income
Finance cost
Finance income - net
Net
6-K
2cf2e8j9
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.1
ssk v34ud
5 Jun 23
Current report (foreign)
4:28pm
6-K
EX-99.1
btjxa4epg tqkd
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
6-K
EX-99.1
xc2ij
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
pf6u4hohlxpk6g4uo
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-3/A
0a4p2scb9q6h046
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
6-K
EX-99.1
7w7f 9hlevrr7tduf4ix
10 Jun 22
Current report (foreign)
6:05am
F-3/A
zwqq435md
20 May 22
Shelf registration (foreign) (amended)
6:54pm
F-3
ceva4r7m
15 Apr 22
Shelf registration (foreign)
5:27pm
6-K
EX-99.1
4j26hvx
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
20-F
EX-4.12
6k9nk
31 Mar 22
Annual report (foreign)
4:33pm
20-F
zpcsmsg
31 Mar 22
Annual report (foreign)
4:33pm
6-K
m9oz2aku 1s3ui4io956
1 Mar 22
Current report (foreign)
4:16pm
6-K
EX-99.1
bp1n8fygr1qluix
16 Feb 22
Current report (foreign)
4:01pm